EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lower, Earlier, Longer and Personalized: Rethinking Lipid‐Lowering Therapy for Cardiovascular Prevention

Chiara Dalla Valle iD, Marco Zuin iD, Claudio Bilato iD

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70267 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Chiara Dalla Valle und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, West Vicenza General Hospitals, Vicenza, Italy. Hauptthemen laut MEDLINE: Hypolipidemic Agents, Cardiovascular Diseases, Atherosclerosis, Dyslipidemias. Die Arbeit nennt 137 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Lipid‐lowering therapy represents the cornerstone of cardiovascular prevention, with low‐density lipoproteins (LDL) identified as a causal factor in atherosclerosis. Last decades have seen a rapid expansion in therapeutic options beyond statins, including ezetimibe, bempedoic acid, proprotein convertase subtilisin/kexin Type 9 inhibitors, both monoclonal antibodies and small interfering RNA therapies, and emerging agents targeting novel pathways. Current treatment paradigms emphasize early risk stratification, aggressive LDL‐cholesterol (LDL‐C) control in high‐risk individuals and systematic combination therapy when treatment goals cannot be achieved with statins alone. In addition, growing attention is being paid to residual cardiovascular risk associated with triglyceride‐rich lipoproteins and lipoprotein (a) [Lp(a)]. Novel pharmacological approaches targeting these pathways are currently under investigation and may substantially modify the future landscape of lipid management. This review summarizes current strategies for lipid‐lowering therapy across different cardiovascular risk categories and discusses emerging therapies targeting LDL‐C, triglyceride‐rich lipoproteins and Lp(a), highlighting future directions in precision lipidology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypolipidemic AgentsCardiovascular DiseasesAtherosclerosisDyslipidemiasHumansCholesterol, LDLLipoprotein(a)TriglyceridesPCSK9 InhibitorsDicarboxylic AcidsFatty AcidsEzetimibeAnticholesteremic AgentsRNA, Small InterferingLipoproteinsAntibodies, MonoclonalHeart Disease Risk FactorsPrecision MedicineNiacinClofibric AcidHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9

Stichwörter der Autor:innen

atherosclerotic cardiovascular diseasecardiovascular preventiondyslipidaemialipid‐lowering therapy

Substanzen

Cholesterol, LDLHypolipidemic AgentsLipoprotein(a)TriglyceridesPCSK9 InhibitorsDicarboxylic AcidsFatty AcidsEzetimibeAnticholesteremic Agents8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid

Autor:innen und Institutionen

  • Division of Cardiology, West Vicenza General Hospitals, Vicenza, Italy.
  • Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  • Division of Cardiology, South Padova General Hospitals, Padova, Italy.

ORCID-Profile: Chiara Dalla Valle, Marco Zuin, Claudio Bilato

Zitieren

APA

Valle, C. D., Zuin, M., & Bilato, C. (2026). Lower, Earlier, Longer and Personalized: Rethinking Lipid‐Lowering Therapy for Cardiovascular Prevention. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70267

Vancouver

Valle CD, Zuin M, Bilato C. Lower, Earlier, Longer and Personalized: Rethinking Lipid‐Lowering Therapy for Cardiovascular Prevention. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70267

BibTeX
@article{Valle2026,
  author = {Valle, Chiara Dalla and Zuin, Marco and Bilato, Claudio},
  title = {Lower, Earlier, Longer and Personalized: Rethinking Lipid‐Lowering Therapy for Cardiovascular Prevention},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70267}
}
Kostenlos starten →